Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Intuit Inc. (INTU) vs Novavax Inc (NVAX) Price & Performance

Intuit Inc.Trade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Intuit Inc. vs Novavax Inc — how do they compare? Intuit Inc. trades at $331.08 (market cap $92.03B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Intuit Inc. is far larger — about 70.3× Novavax Inc's market cap, and Intuit Inc. pays a 1.43% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

INTUNVAX
Market Cap
$92.03B$1.31B
Sector
TechnologyHealth
52-Week High
$717.21$11.19
52-Week Low
$255.07$6.22
Enterprise Value
$90.49B$889.30M
Dividend Yield
1.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Intuit Inc.

Intuit (INTU) trades at $334.43, up 2.82% today, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. However, the stock faces headwinds from legal investigations into pricing disclosures and a recent 20% drop, as reported by Forbes on June 2, 2026.

The outlook is mixed: analyst consensus targets $402.26 (66.7% buy ratings), but legal risks and overbought RSI levels near 74.42 suggest caution. Revenue growth to $20.9B in 2026 and a high net margin of 21.9% support long-term value, yet near-term volatility may persist due to sentiment shifts.

Novavax Inc

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Intuit Inc.

Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.

Read more on INTU

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX